Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2020 May 15;26(8):1552–1556. doi: 10.1016/j.bbmt.2020.04.010

Figure 3: PGDHi improves the efficacy of low-dose cyclosporine in murine aplastic anemia.

Figure 3:

(A) Complete blood count analysis of radiation alone controls (Rad Ctrl), and aplastic anemia mice treated with PGDHi, vehicle (Veh) control, PGDHi + 10mg/kg cyclosporine (CsA), and Veh + CsA, 13 days post-induction. Panels represent total white blood cells (WBC), neutrophils (NE), platelets (PLT), and red blood cells (RBCs). N= 11-12 experimental mice/group. (B) Representative hematoxylin and eosin-stained sections from the hindlimbs of Rad Ctrl and aplastic anemia mice treated as indicated, 14 days post-induction. (C-D) Quantification of bone marrow (BM) cellularity and absolute number of BM Lin− c-Kit+ -defined hematopoietic stem and progenitor cells (HSPCs) perhindlimb, 14 days post-induction. N=10-11 experimental mice/group. * P < 0.05 for the comparison of either mono- or dual-PGDHi therapy versus vehicle-treated counterpart by student’s t-test; ψ P < 0.05 by one-way ANOVA with Tukey multiple comparisons post-test.